Telomir Pharmaceuticals, Inc. (TELO)Healthcare | Biotechnology | Miami, United States | NasdaqCM
1.24 USD
+0.01
(0.813%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 1.25 +0.01 (0.694%) ⇧ (July 13, 2026, 6:58 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:03 a.m. EDT
The immediate outlook is severely compromised by a catastrophic collapse in share price, which has erased over 70% of the company's value in just twelve months. This steep decline is compounded by a complete absence of profitability, with negative earnings per share and significant cash burn that depletes limited resources. While the company recently secured FDA clearance for a new trial and completed an acquisition, these strategic milestones cannot currently offset the market's verdict on the deteriorating financial reality. With no dividend to provide income and a balance sheet showing substantial debt relative to equity, the investment case relies entirely on a future turnaround that remains unproven. The statistical models offer no guidance, reflecting the extreme volatility and lack of predictable patterns in such a distressed biotech environment. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.104812 |
| AutoETS | 0.108568 |
| MSTL | 0.116249 |
| AutoTheta | 0.130401 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 1.31 |
| Ljung-Box p | 0.002 |
| Jarque-Bera p | 0.005 |
| Excess Kurtosis | 1.15 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 11.037 |
| Market Cap | 85,280,952 |
| Forward P/E | -4.43 |
| Beta | -0.24 |
| Website | https://telomirpharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.05128205 |
| Address1 | 100 SE 2nd Street |
| Address2 | Suite 2000 #1009 |
| All Time High | 20.72 |
| All Time Low | 1.05 |
| Ask | 1.57 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 56,850 |
| Average Daily Volume3 Month | 153,834 |
| Average Volume | 153,834 |
| Average Volume10Days | 56,850 |
| Beta | -0.244 |
| Bid | 0.8856 |
| Bid Size | 2 |
| Book Value | 0.144 |
| City | Miami |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.24 |
| Current Ratio | 6.998 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.25 |
| Day Low | 1.21 |
| Debt To Equity | 11.037 |
| Display Name | Telomir Pharmaceuticals |
| Earnings Timestamp End | 1,755,288,000 |
| Earnings Timestamp Start | 1,754,942,400 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 80,268,128 |
| Eps Forward | -0.28 |
| Eps Trailing Twelve Months | -0.29 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.2782 |
| Fifty Day Average Change | -0.03820002 |
| Fifty Day Average Change Percent | -0.029885793 |
| Fifty Two Week Change Percent | 5.128205 |
| Fifty Two Week High | 3.1 |
| Fifty Two Week High Change | -1.8599999 |
| Fifty Two Week High Change Percent | -0.59999996 |
| Fifty Two Week Low | 1.05 |
| Fifty Two Week Low Change | 0.19000006 |
| Fifty Two Week Low Change Percent | 0.18095244 |
| Fifty Two Week Range | 1.05 - 3.1 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,707,489,000,000 |
| Float Shares | 47,511,803 |
| Forward Eps | -0.28 |
| Forward P E | -4.428571 |
| Free Cashflow | -1,496,645 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.35105 |
| Held Percent Institutions | 0.03257 |
| Implied Shares Outstanding | 68,774,956 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-02-09 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida. |
| Long Name | Telomir Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 85,280,952 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1831658436 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -9,224,324 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 84,593,195 |
| Open | 1.21 |
| Operating Cashflow | -4,598,566 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 786 396 6723 |
| Post Market Change | 0.008599997 |
| Post Market Change Percent | 0.6935481 |
| Post Market Price | 1.2486 |
| Post Market Time | 1,783,983,487 |
| Previous Close | 1.23 |
| Price Hint | 4 |
| Price To Book | 8.611112 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.721 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.00999999 |
| Regular Market Change Percent | 0.813007 |
| Regular Market Day High | 1.25 |
| Regular Market Day Low | 1.21 |
| Regular Market Day Range | 1.21 - 1.25 |
| Regular Market Open | 1.21 |
| Regular Market Previous Close | 1.23 |
| Regular Market Price | 1.24 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 35,087 |
| Return On Assets | -1.86929 |
| Return On Equity | -3.8425698 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 68,774,956 |
| Shares Percent Shares Out | 0.0139 |
| Shares Short | 953,308 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 923,133 |
| Short Name | Telomir Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0173 |
| Short Ratio | 6.82 |
| Source Interval | 15 |
| State | FL |
| Symbol | TELO |
| Total Cash | 5,560,511 |
| Total Cash Per Share | 0.081 |
| Total Debt | 547,695 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.29 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.3414 |
| Two Hundred Day Average Change | -0.10140002 |
| Two Hundred Day Average Change Percent | -0.075592674 |
| Type Disp | Equity |
| Volume | 35,087 |
| Website | https://telomirpharma.com |
| Zip | 33,131 |